169 related articles for article (PubMed ID: 20235889)
1. Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.
Kinder B; McCormack FX
Lymphat Res Biol; 2010 Mar; 8(1):71-9. PubMed ID: 20235889
[TBL] [Abstract][Full Text] [Related]
2. Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis.
Kinder BW; Sherman AC; Young LR; Hagaman JT; Oprescu N; Byrnes S; McCormack FX
Respir Med; 2010 Apr; 104(4):578-83. PubMed ID: 19962873
[TBL] [Abstract][Full Text] [Related]
3. The changing face of a rare disease: lymphangioleiomyomatosis.
Harari S; Torre O; Cassandro R; Moss J
Eur Respir J; 2015 Nov; 46(5):1471-85. PubMed ID: 26405290
[TBL] [Abstract][Full Text] [Related]
4. The International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform.
Nurok M; Eslick I; Carvalho CR; Costabel U; D'Armiento J; Glanville AR; Harari S; Henske EP; Inoue Y; Johnson SR; Lacronique J; Lazor R; Moss J; Ruoss SJ; Ryu JH; Seyama K; Watz H; Xu KF; Hohmann EL; Moss F
Lymphat Res Biol; 2010 Mar; 8(1):81-7. PubMed ID: 20235890
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.
Juvet SC; McCormack FX; Kwiatkowski DJ; Downey GP
Am J Respir Cell Mol Biol; 2007 Apr; 36(4):398-408. PubMed ID: 17099139
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target.
Abdelwahab EMM; Pal S; Kvell K; Sarosi V; Bai P; Rue R; Krymskaya V; McPhail D; Porter A; Pongracz JE
Oncogene; 2019 Apr; 38(16):3093-3101. PubMed ID: 30573768
[TBL] [Abstract][Full Text] [Related]
7. The diagnosis of cystic lung diseases: a role for bronchoalveolar lavage and transbronchial biopsy?
Torre O; Harari S
Respir Med; 2010 Jul; 104 Suppl 1():S81-5. PubMed ID: 20430602
[TBL] [Abstract][Full Text] [Related]
8. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.
El-Chemaly S; Henske EP
Expert Rev Respir Med; 2015 Apr; 9(2):195-204. PubMed ID: 25757365
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis (LAM) Cell Atlas.
Du Y; Guo M; Wu Y; Wagner A; Perl AK; Wikenheiser-Brokamp K; Yu J; Gupta N; Kopras E; Krymskaya V; Obraztsova K; Tang Y; Kwiatkowski D; Henske EP; McCormack F; Xu Y
Thorax; 2023 Jan; 78(1):85-87. PubMed ID: 36599466
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis suspected to be a gynecologic disease.
Yamashita S; Nakamura K; Shinozaki H; Minegishi T
J Obstet Gynaecol Res; 2011 Mar; 37(3):267-9. PubMed ID: 21314806
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.
McCarthy C; Lara Gallego B; Trapnell BC; McCormack FX
Adv Exp Med Biol; 2017; 1031():419-442. PubMed ID: 29214586
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis.
Bittmann I; Rolf B; Amann G; Löhrs U
Hum Pathol; 2003 Jan; 34(1):95-8. PubMed ID: 12605373
[TBL] [Abstract][Full Text] [Related]
14. Lymphatic manifestations of lymphangioleiomyomatosis.
Gupta R; Kitaichi M; Inoue Y; Kotloff R; McCormack FX
Lymphology; 2014 Sep; 47(3):106-17. PubMed ID: 25420303
[TBL] [Abstract][Full Text] [Related]
15. Orphan Lung Diseases.
Ali MS; Ghori UK; Musani AI
Med Clin North Am; 2019 May; 103(3):503-515. PubMed ID: 30955517
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis.
Valencia JC; Pacheco-Rodriguez G; Carmona AK; Xavier J; Bruneval P; Riemenschneider WK; Ikeda Y; Yu ZX; Ferrans VJ; Moss J
Am J Respir Cell Mol Biol; 2006 Jul; 35(1):40-7. PubMed ID: 16474096
[TBL] [Abstract][Full Text] [Related]
18. Lymphangioleiomyomatosis.
Johnson SR
Eur Respir J; 2006 May; 27(5):1056-65. PubMed ID: 16707400
[TBL] [Abstract][Full Text] [Related]
19. [Lymphangioleiomyomatosis - new concepts on pathogenesis, diagnosis and treatment].
Sobiecka M
Wiad Lek; 2016; 69(2 Pt 1):123-9. PubMed ID: 27421126
[TBL] [Abstract][Full Text] [Related]
20. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
